DYANAVEL XR 10 (Amphetamine; Amphetamine Aspartate/Dextroamphetamine Sulfate) Patent Expiration, LOE Window & CMS Spending

DYANAVEL XR 10 (Amphetamine; Amphetamine Aspartate/Dextroamphetamine Sulfate) by Tris: FDA Orange Book core substance LOE 2038-09-24 (last listed 2040-02-11), 0 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTris
FDA Application & PathwayN210526 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2038-09-24
Last Listed Patent or Exclusivity Date2040-02-11
Orange Book Patents (*PED Extensions)24 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel